Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming
Despite aggressive combination chemotherapy and surgery, outcomes for patients with osteosarcoma have remained stagnant for more than 25 years, and numerous clinical trials have identified no new therapies. p53 deletion or mutation is found in more than 80% of osteosarcoma tumors. In p53-deficient c...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/14/17/4310 |
| _version_ | 1797496058559856640 |
|---|---|
| author | Yuanzheng Yang Zhanglong Peng Elsa R. Flores Eugenie S. Kleinerman |
| author_facet | Yuanzheng Yang Zhanglong Peng Elsa R. Flores Eugenie S. Kleinerman |
| author_sort | Yuanzheng Yang |
| collection | DOAJ |
| description | Despite aggressive combination chemotherapy and surgery, outcomes for patients with osteosarcoma have remained stagnant for more than 25 years, and numerous clinical trials have identified no new therapies. p53 deletion or mutation is found in more than 80% of osteosarcoma tumors. In p53-deficient cancers with structurally altered p63 and p73, interfering with tumor cell metabolism using Pramlintide (an FDA-approved drug for type 2 diabetes) results in tumor regression. Pramlintide response is mediated through upregulation of islet amyloid polypeptide (IAPP). Here, we showed that osteosarcoma cells have altered p63, p73, and p53, and decreased IAPP expression but have the two main IAPP receptors, CalcR and RAMP3, which inhibit glycolysis and induce apoptosis. We showed that in osteosarcoma cells with high- or mid-range glycolytic activity, Pramlintide decreased cell glycolysis, resulting in decreased proliferation and increased apoptosis in vitro. In contrast, Pramlintide had no effect in osteosarcoma cells with low glycolytic activity. Using a subcutaneous osteosarcoma mouse model, we showed that intratumoral injection of Pramlintide-induced tumor regression. Tumor sections showed increased apoptosis and a decrease in Ki-67 and HIF-1α. These data suggest that in osteosarcoma cells with altered p53, p63, and p73 and a high glycolytic function, Pramlintide therapy can modulate metabolic programming and inhibit tumor growth. |
| first_indexed | 2024-03-10T01:58:14Z |
| format | Article |
| id | doaj.art-d46c28d55097405896351ada7ba9d3e2 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T01:58:14Z |
| publishDate | 2022-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-d46c28d55097405896351ada7ba9d3e22023-11-23T12:53:26ZengMDPI AGCancers2072-66942022-09-011417431010.3390/cancers14174310Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic ReprogrammingYuanzheng Yang0Zhanglong Peng1Elsa R. Flores2Eugenie S. Kleinerman3Department of Pediatrics Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Pediatrics Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADepartment of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USADepartment of Pediatrics Research, Division of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USADespite aggressive combination chemotherapy and surgery, outcomes for patients with osteosarcoma have remained stagnant for more than 25 years, and numerous clinical trials have identified no new therapies. p53 deletion or mutation is found in more than 80% of osteosarcoma tumors. In p53-deficient cancers with structurally altered p63 and p73, interfering with tumor cell metabolism using Pramlintide (an FDA-approved drug for type 2 diabetes) results in tumor regression. Pramlintide response is mediated through upregulation of islet amyloid polypeptide (IAPP). Here, we showed that osteosarcoma cells have altered p63, p73, and p53, and decreased IAPP expression but have the two main IAPP receptors, CalcR and RAMP3, which inhibit glycolysis and induce apoptosis. We showed that in osteosarcoma cells with high- or mid-range glycolytic activity, Pramlintide decreased cell glycolysis, resulting in decreased proliferation and increased apoptosis in vitro. In contrast, Pramlintide had no effect in osteosarcoma cells with low glycolytic activity. Using a subcutaneous osteosarcoma mouse model, we showed that intratumoral injection of Pramlintide-induced tumor regression. Tumor sections showed increased apoptosis and a decrease in Ki-67 and HIF-1α. These data suggest that in osteosarcoma cells with altered p53, p63, and p73 and a high glycolytic function, Pramlintide therapy can modulate metabolic programming and inhibit tumor growth.https://www.mdpi.com/2072-6694/14/17/4310osteosarcomapramlintideIAPPp53p63p73 |
| spellingShingle | Yuanzheng Yang Zhanglong Peng Elsa R. Flores Eugenie S. Kleinerman Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming Cancers osteosarcoma pramlintide IAPP p53 p63 p73 |
| title | Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming |
| title_full | Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming |
| title_fullStr | Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming |
| title_full_unstemmed | Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming |
| title_short | Pramlintide: A Novel Therapeutic Approach for Osteosarcoma through Metabolic Reprogramming |
| title_sort | pramlintide a novel therapeutic approach for osteosarcoma through metabolic reprogramming |
| topic | osteosarcoma pramlintide IAPP p53 p63 p73 |
| url | https://www.mdpi.com/2072-6694/14/17/4310 |
| work_keys_str_mv | AT yuanzhengyang pramlintideanoveltherapeuticapproachforosteosarcomathroughmetabolicreprogramming AT zhanglongpeng pramlintideanoveltherapeuticapproachforosteosarcomathroughmetabolicreprogramming AT elsarflores pramlintideanoveltherapeuticapproachforosteosarcomathroughmetabolicreprogramming AT eugenieskleinerman pramlintideanoveltherapeuticapproachforosteosarcomathroughmetabolicreprogramming |